CATALINA-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6 (CLDN6)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517190-24-00

Acronym

TORL123-002

Enrollment

159

Registered

2025-07-07

Start date

2025-09-16

Completion date

Unknown

Last updated

2026-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer

Brief summary

Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (as defined by confirmed best overall response of partial or complete responses) by blinded independent central review (BICR).

Interventions

DRUGTORL-1-23

DRUGPEGFILGRASTIM

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (as defined by confirmed best overall response of partial or complete responses) by blinded independent central review (BICR).	—

Countries

Austria, Belgium, Czechia, France, Germany, Ireland, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026